Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Benchmark has reiterated its Hold rating on AbCellera Biologics (NASDAQ:ABCL), according to a research note published this week. The company, currently valued at $1.36 billion, has seen its stock surge 45.73% year-to-date, though InvestingPro analysis suggests the stock is currently fairly valued.
The company reported second-quarter 2025 revenues of $17.1 million, up from $7.3 million in the same period last year. The revenue increase was primarily driven by a milestone payment related to a Trianni license.
AbCellera posted a net loss of $30.4 million or ($0.12) per share for the quarter, compared to a net loss of $37.2 million or ($0.13) per share in the second quarter of 2024. Benchmark had estimated revenues of $5.2 million and a net loss of ($0.15) per share.
The biotechnology company announced it has initiated discovery on five additional partner-initiated programs and advanced its third internal R&D program, ABCL688, into IND/CTA-enabling studies.
Benchmark maintained its Hold rating as AbCellera reduces its revenue-generating development partnership activities and shifts focus toward internal pipeline development.
In other recent news, AbCellera Biologics Inc reported second-quarter revenue that significantly surpassed analyst expectations. The company posted revenue of $17.1 million for the second quarter of 2025, more than doubling the analyst consensus estimate of $7.45 million. This figure also marks a 134% increase from the $7.3 million reported in the same quarter last year. Additionally, AbCellera reported a quarterly loss of -$0.12 per share, which was better than analysts’ expectations of -$0.14 per share and an improvement from the -$0.13 per share loss reported in the second quarter of 2024. The company also announced its transition to a clinical-stage biotechnology firm. These developments have captured the attention of investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.